{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T02:45:32Z","timestamp":1771987532110,"version":"3.50.1"},"reference-count":195,"publisher":"Bentham Science Publishers Ltd.","issue":"3","funder":[{"DOI":"10.13039\/501100004569","name":"Ministry of Science and Higher Education","doi-asserted-by":"publisher","award":["2012\/05\/N\/NZ5\/02616"],"award-info":[{"award-number":["2012\/05\/N\/NZ5\/02616"]}],"id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCDT"],"published-print":{"date-parts":[[2020,3,19]]},"abstract":"<jats:sec><jats:title>:<\/jats:title><jats:p>Peroxisome proliferator-activated receptor-gamma (PPAR\u03b3) is a nuclear receptor acting as a transcription factor involved in the regulation of energy metabolism, cell cycle, cell differentiation, and apoptosis. These unique properties constitute a strong therapeutic potential that place PPAR\u03b3 agonists as one of the most interesting and widely studied anticancer molecules.<\/jats:p><\/jats:sec><jats:sec><jats:title>:<\/jats:title><jats:p>Although PPAR\u03b3 agonists exert significant, antiproliferative and tumoricidal activity in vitro, their anticancer efficacy in animal models is ambiguous, and their effectiveness in clinical trials in monotherapy is unsatisfactory. However, due to pleiotropic effects of PPAR\u03b3 activation in normal and tumor cells, PPAR\u03b3 ligands interact with many antitumor treatment modalities and synergistically potentiate their effectiveness. The most spectacular example is a combination of PPAR\u03b3 ligands with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). In this setting, PPAR\u03b3 activation sensitizes leukemic stem cells, resistant to any previous form of treatment, to targeted therapy. Thus, this combination is believed to be the first pharmacological therapy able to cure CML patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>:<\/jats:title><jats:p>Within the last decade, a significant body of data confirming the benefits of the addition of PPAR\u03b3 ligands to various antitumor therapies, including chemotherapy, hormonotherapy, targeted therapy, and immunotherapy, has been published. Although the majority of these studies have been carried out in vitro or animal tumor models, a few successful attempts to introduce PPAR\u03b3 ligands into anticancer therapy in humans have been recently made. In this review, we aim to summarize shines and shadows of targeting PPAR\u03b3 in antitumor therapies.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1568009619666191209102015","type":"journal-article","created":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T13:42:07Z","timestamp":1575898927000},"page":"197-215","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["PPAR\u03b3 Agonists in Combination Cancer Therapies"],"prefix":"10.2174","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4300-7267","authenticated-orcid":true,"given":"Piotr","family":"Mrowka","sequence":"first","affiliation":[{"name":"Department of Biophysics and Human Physiology, Medical University of Warsaw, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5865-8425","authenticated-orcid":true,"given":"Eliza","family":"Glodkowska-Mrowka","sequence":"additional","affiliation":[{"name":"Department of Laboratory Diagnostics and Clinical Immunology of Developmental Age, Medical University of Warsaw, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.12688\/f1000research.14136.1","volume":"7","author":"Choi S.H.","year":"2018","unstructured":"Choi S.H.; Chung S.S.; Park K.S.; Re-highlighting the action of PPAR\u03b3 in treating metabolic diseases. F1000 Res 2018,7,7","journal-title":"F1000 Res"},{"key":"ref=2","first-page":"281","volume":"4","author":"Greene M.E.","year":"1995","unstructured":"Greene M.E.; Blumberg B.; McBride O.W.; Yi H.F.; Kronquist K.; Kwan K.; Hsieh L.; Greene G.; Nimer S.D.; Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr 1995,4(4-5),281-299","journal-title":"Gene Expr"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1101\/gad.11.15.1987","volume":"11","author":"Altiok S.","year":"1997","unstructured":"Altiok S.; Xu M.; Spiegelman B.M.; PPARgamma induces cell cycle withdrawal: Inhibition of E2F\/DP DNA-binding activity via down-regulation of PP2A. Genes Dev 1997,11(15),1987-1998","journal-title":"Genes Dev"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1097-2765(00)80047-7","volume":"1","author":"Mueller E.","year":"1998","unstructured":"Mueller E.; Sarraf P.; Tontonoz P.; Evans R.M.; Martin K.J.; Zhang M.; Fletcher C.; Singer S.; Spiegelman B.M.; Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998,1(3),465-470","journal-title":"Mol Cell"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1073\/pnas.96.7.3951","volume":"96","author":"Demetri G.D.","year":"1999","unstructured":"Demetri G.D.; Fletcher C.D.; Mueller E.; Sarraf P.; Naujoks R.; Campbell N.; Spiegelman B.M.; Singer S.; Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 1999,96(7),3951-3956","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.bbalip.2007.01.007","volume":"1771","author":"Zoete V.","year":"2007","unstructured":"Zoete V.; Grosdidier A.; Michielin O.; Peroxisome proliferator-activated receptor structures: Ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta 2007,1771(8),915-925","journal-title":"Biochim Biophys Acta"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/355446a0","volume":"355","author":"Kliewer S.A.","year":"1992","unstructured":"Kliewer S.A.; Umesono K.; Mangelsdorf D.J.; Evans R.M.; Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 1992,355(6359),446-449","journal-title":"Nature"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"28210","DOI":"10.1074\/jbc.272.45.28210","volume":"272","author":"Martin G.","year":"1997","unstructured":"Martin G.; Schoonjans K.; Lefebvre A.M.; Staels B.; Auwerx J.; Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem 1997,272(45),28210-28217","journal-title":"J Biol Chem"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"16710","DOI":"10.1074\/jbc.273.27.16710","volume":"273","author":"Motojima K.","year":"1998","unstructured":"Motojima K.; Passilly P.; Peters J.M.; Gonzalez F.J.; Latruffe N.; Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. J Biol Chem 1998,273(27),16710-16714","journal-title":"J Biol Chem"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.mito.2008.02.001","volume":"8","author":"Alaynick W.A.","year":"2008","unstructured":"Alaynick W.A.; Nuclear receptors, mitochondria and lipid metabolism. Mitochondrion 2008,8(4),329-337","journal-title":"Mitochondrion"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1158\/1078-0432.CCR-08-0326","volume":"15","author":"Ondrey F.","year":"2009","unstructured":"Ondrey F.; Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: Implications for chemoprevention. Clin Cancer Res 2009,15(1),2-8","journal-title":"Clin Cancer Res"},{"key":"ref=12","first-page":"25-34","volume":"6","author":"Blanquicett C.","year":"2008","unstructured":"Blanquicett C.; Roman J.; Hart C.M.; Thiazolidinediones as anti-cancer agents. Cancer Ther 2008,6(A),25-34","journal-title":"Cancer Ther"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.canlet.2008.08.008","volume":"276","author":"Wei S.","year":"2009","unstructured":"Wei S.; Yang J.; Lee S.L.; Kulp S.K.; Chen C.S.; PPARgamma-independent antitumor effects of thiazolidinediones. Cancer Lett 2009,276(2),119-124","journal-title":"Cancer Lett"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2174\/1568011033482431","volume":"3","author":"Theocharisa S.","year":"2003","unstructured":"Theocharisa S.; Margeli A.; Kouraklis G.; Peroxisome proliferator activated receptor-gamma ligands as potent antineoplastic agents. Curr Med Chem Anticancer Agents 2003,3(3),239-251","journal-title":"Curr Med Chem Anticancer Agents"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nrc1254","volume":"4","author":"Michalik L.","year":"2004","unstructured":"Michalik L.; Desvergne B.; Wahli W.; Peroxisome-proliferator-activated receptors and cancers: Complex stories. Nat Rev Cancer 2004,4(1),61-70","journal-title":"Nat Rev Cancer"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ctrv.2004.04.004","volume":"30","author":"Theocharis S.","year":"2004","unstructured":"Theocharis S.; Margeli A.; Vielh P.; Kouraklis G.; Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators. Cancer Treat Rev 2004,30(6),545-554","journal-title":"Cancer Treat Rev"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.2174\/092986709788186165","volume":"16","author":"Farce A.","year":"2009","unstructured":"Farce A.; Renault N.; Chavatte P.; Structural insight into PPARgamma ligands binding. Curr Med Chem 2009,16(14),1768-1789","journal-title":"Curr Med Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"19152","DOI":"10.1074\/jbc.M702724200","volume":"282","author":"Feige J.N.","year":"2007","unstructured":"Feige J.N.; Gelman L.; Rossi D.; Zoete V.; M\u00e9tivier R.; Tudor C.; Anghel S.I.; Grosdidier A.; Lathion C.; Engelborghs Y.; Michielin O.; Wahli W.; Desvergne B.; The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis. J Biol Chem 2007,282(26),19152-19166","journal-title":"J Biol Chem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1517\/14740338.2011.534982","volume":"10","author":"Tolman K.G.","year":"2011","unstructured":"Tolman K.G.; The safety of thiazolidinediones. Expert Opin Drug Saf 2011,10(3),419-428","journal-title":"Expert Opin Drug Saf"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.jdiacomp.2016.04.004","volume":"30","author":"Davidson M.B.","year":"2016","unstructured":"Davidson M.B.; Pioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence. J Diabetes Complications 2016,30(6),981-985","journal-title":"J Diabetes Complications"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/pds.4154","volume":"26","author":"Hampp C.","year":"2017","unstructured":"Hampp C.; Pippins J.; Pioglitazone and bladder cancer: FDA\u2019s assessment. Pharmacoepidemiol Drug Saf 2017,26(2),117-118","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","volume":"298","author":"Lincoff A.M.","year":"2007","unstructured":"Lincoff A.M.; Wolski K.; Nicholls S.J.; Nissen S.E.; Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. JAMA 2007,298(10),1180-1188","journal-title":"JAMA"},{"key":"ref=23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134842","volume":"10","author":"Kim J.","year":"2015","unstructured":"Kim J.; Sato M.; Choi J.W.; Kim H.W.; Yeh B.I.; Larsen J.E.; Minna J.D.; Cha J.H.; Jeong Y.; Nuclear receptor expression and function in human lung cancer pathogenesis. PLoS One 2015,10(8)","journal-title":"PLoS One"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.4103\/aja.aja_15_17","volume":"20","author":"Elix C.","year":"2018","unstructured":"Elix C.; Pal S.K.; Jones J.O.; The role of peroxisome proliferator-activated receptor gamma in prostate cancer. Asian J Androl 2018,20(3),238-243","journal-title":"Asian J Androl"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4161\/cbt.8.7.7853","volume":"8","author":"Mansure J.J.","year":"2009","unstructured":"Mansure J.J.; Nassim R.; Kassouf W.; Peroxisome proliferator-activated receptor gamma in bladder cancer: A promising therapeutic target. Cancer Biol Ther 2009,8(7),6-15","journal-title":"Cancer Biol Ther"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1007\/s10620-007-9794-4","volume":"52","author":"Theocharis S.","year":"2007","unstructured":"Theocharis S.; Giaginis C.; Parasi A.; Margeli A.; Kakisis J.; Agapitos E.; Kouraklis G.; Expression of peroxisome proliferator-activated receptor-gamma in colon cancer: Correlation with histopathological parameters, cell cycle-related molecules, and patients\u2019 survival. Dig Dis Sci 2007,52(9),2305-2311","journal-title":"Dig Dis Sci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10549-015-3348-9","volume":"150","author":"Abduljabbar R.","year":"2015","unstructured":"Abduljabbar R.; Al-Kaabi M.M.; Negm O.H.; Jerjees D.; Muftah A.A.; Mukherjee A.; Lai C.F.; Buluwela L.; Ali S.; Tighe P.J.; Green A.; Ellis I.; Rakha E.; Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer. Breast Cancer Res Treat 2015,150(3),511-522","journal-title":"Breast Cancer Res Treat"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1089\/thy.2005.15.997","volume":"15","author":"Karger S.","year":"2005","unstructured":"Karger S.; Berger K.; Eszlinger M.; Tannapfel A.; Dralle H.; Paschke R.; F\u00fchrer D.; Evaluation of peroxisome proliferator-activated receptor-gamma expression in benign and malignant thyroid pathologies. Thyroid 2005,15(9),997-1003","journal-title":"Thyroid"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1038\/sj.onc.1207399","volume":"23","author":"Gregory Powell J.","year":"2004","unstructured":"Gregory Powell J.; Wang X.; Allard B.L.; Sahin M.; Wang X.L.; Hay I.D.; Hiddinga H.J.; Deshpande S.S.; Kroll T.G.; Grebe S.K.; Eberhardt N.L.; McIver B.; The PAX8\/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition. Oncogene 2004,23(20),3634-3641","journal-title":"Oncogene"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0014-5793(99)00871-6","volume":"455","author":"Takahashi N.","year":"1999","unstructured":"Takahashi N.; Okumura T.; Motomura W.; Fujimoto Y.; Kawabata I.; Kohgo Y.; Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 1999,455(1-2),135-139","journal-title":"FEBS Lett"},{"key":"ref=31","first-page":"1129","volume":"60","author":"Chang T.H.","year":"2000","unstructured":"Chang T.H.; Szabo E.; Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res 2000,60(4),1129-1138","journal-title":"Cancer Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/2030","volume":"4","author":"Sarraf P.","year":"1998","unstructured":"Sarraf P.; Mueller E.; Jones D.; King F.J.; DeAngelo D.J.; Partridge J.B.; Holden S.A.; Chen L.B.; Singer S.; Fletcher C.; Spiegelman B.M.; Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998,4(9),1046-1052","journal-title":"Nat Med"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0016-5085(98)70072-1","volume":"115","author":"Brockman J.A.","year":"1998","unstructured":"Brockman J.A.; Gupta R.A.; Dubois R.N.; Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 1998,115(5),1049-1055","journal-title":"Gastroenterology"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1016\/j.biocel.2009.06.007","volume":"41","author":"Zhou J.","year":"2009","unstructured":"Zhou J.; Zhang W.; Liang B.; Casimiro M.C.; Whitaker-Menezes D.; Wang M.; Lisanti M.P.; Lanza-Jacoby S.; Pestell R.G.; Wang C.; PPARgamma activation induces autophagy in breast cancer cells. Int J Biochem Cell Biol 2009,41(11),2334-2342","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1124\/mol.107.034371","volume":"71","author":"Soller M.","year":"2007","unstructured":"Soller M.; Dr\u00f6se S.; Brandt U.; Br\u00fcne B.; von Knethen A.; Mechanism of thiazolidinedione-dependent cell death in Jurkat T cells. Mol Pharmacol 2007,71(6),1535-1544","journal-title":"Mol Pharmacol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1038\/onc.2009.118","volume":"28","author":"Kar R.","year":"2009","unstructured":"Kar R.; Singha P.K.; Venkatachalam M.A.; Saikumar P.; A novel role for MAP1 LC3 in nonautophagic cytoplasmic vacuolation death of cancer cells. Oncogene 2009,28(28),2556-2568","journal-title":"Oncogene"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0014-2999(00)00758-5","volume":"407","author":"Okura T.","year":"2000","unstructured":"Okura T.; Nakamura M.; Takata Y.; Watanabe S.; Kitami Y.; Hiwada K.; Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells. Eur J Pharmacol 2000,407(3),227-235","journal-title":"Eur J Pharmacol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/S0960-9822(01)00225-1","volume":"11","author":"Patel L.","year":"2001","unstructured":"Patel L.; Pass I.; Coxon P.; Downes C.P.; Smith S.A.; Macphee C.H.; Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol 2001,11(10),764-768","journal-title":"Curr Biol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0006-291X(02)02983-2","volume":"301","author":"Farrow B.","year":"2003","unstructured":"Farrow B.; Evers B.M.; Activation of PPARgamma increases PTEN expression in pancreatic cancer cells. Biochem Biophys Res Commun 2003,301(1),50-53","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1158\/1535-7163.MCT-05-0347","volume":"5","author":"Han S.","year":"2006","unstructured":"Han S.; Roman J.; Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways. Mol Cancer Ther 2006,5(2),430-437","journal-title":"Mol Cancer Ther"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"7431","DOI":"10.1074\/jbc.M208076200","volume":"278","author":"Gupta R.A.","year":"2003","unstructured":"Gupta R.A.; Sarraf P.; Brockman J.A.; Shappell S.B.; Raftery L.A.; Willson T.M.; DuBois R.N.; Peroxisome proliferator-activated receptor gamma and transforming growth factor-beta pathways inhibit intestinal epithelial cell growth by regulating levels of TSC-22. J Biol Chem 2003,278(9),7431-7438","journal-title":"J Biol Chem"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1385\/MO:23:3:393","volume":"23","author":"Liu Y.","year":"2006","unstructured":"Liu Y.; Meng Y.; Li H.; Li J.; Fu J.; Liu Y.; Chen X.G.; Growth inhibition and differentiation induced by peroxisome proliferator activated receptor gamma ligand rosiglitazone in human melanoma cell line A375. Med Oncol 2006,23(3),393-402","journal-title":"Med Oncol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.mce.2005.01.011","volume":"233","author":"Lovekamp-Swan T.","year":"2005","unstructured":"Lovekamp-Swan T.; Chaffin C.L.; The peroxisome proliferator-activated receptor gamma ligand troglitazone induces apoptosis and p53 in rat granulosa cells. Mol Cell Endocrinol 2005,233(1-2),15-24","journal-title":"Mol Cell Endocrinol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1210\/me.2006-0192","volume":"20","author":"Bonofiglio D.","year":"2006","unstructured":"Bonofiglio D.; Aquila S.; Catalano S.; Gabriele S.; Belmonte M.; Middea E.; Qi H.; Morelli C.; Gentile M.; Maggiolini M.; And\u00f2 S.; Peroxisome proliferator-activated receptor-gamma activates p53 gene promoter binding to the nuclear factor-kappaB sequence in human MCF7 breast cancer cells. Mol Endocrinol 2006,20(12),3083-3092","journal-title":"Mol Endocrinol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11010-007-9487-5","volume":"304","author":"Zand H.","year":"2007","unstructured":"Zand H.; Rhimipour A.; Bakhshayesh M.; Shafiee M.; Nour Mohammadi I.; Salimi S.; Involvement of PPAR-gamma and p53 in DHA-induced apoptosis in Reh cells. Mol Cell Biochem 2007,304(1-2),71-77","journal-title":"Mol Cell Biochem"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"21473","DOI":"10.1074\/jbc.272.34.21473","volume":"272","author":"Shao D.","year":"1997","unstructured":"Shao D.; Lazar M.A.; Peroxisome proliferator activated receptor gamma, CCAAT\/enhancer-binding protein alpha, and cell cycle status regulate the commitment to adipocyte differentiation. J Biol Chem 1997,272(34),21473-21478","journal-title":"J Biol Chem"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1172\/JCI200316575","volume":"111","author":"Heaney A.P.","year":"2003","unstructured":"Heaney A.P.; Fernando M.; Melmed S.; PPAR-gamma receptor ligands: Novel therapy for pituitary adenomas. J Clin Invest 2003,111(9),1381-1388","journal-title":"J Clin Invest"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1745-7254.2005.00753.x","volume":"26","author":"Yang F.G.","year":"2005","unstructured":"Yang F.G.; Zhang Z.W.; Xin D.Q.; Shi C.J.; Wu J.P.; Guo Y.L.; Guan Y.F.; Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines. Acta Pharmacol Sin 2005,26(6),753-761","journal-title":"Acta Pharmacol Sin"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1128\/MCB.20.13.4699-4707.2000","volume":"20","author":"Li M.","year":"2000","unstructured":"Li M.; Pascual G.; Glass C.K.; Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol 2000,20(13),4699-4707","journal-title":"Mol Cell Biol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1182\/blood-2004-04-1360","volume":"105","author":"Piva R.","year":"2005","unstructured":"Piva R.; Gianferretti P.; Ciucci A.; Taulli R.; Belardo G.; Santoro M.G.; 15-Deoxy-delta 12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-kappa B activity and down-regulation of antiapoptotic proteins. Blood 2005,105(4),1750-1758","journal-title":"Blood"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/ijc.1470","volume":"94","author":"Kitamura S.","year":"2001","unstructured":"Kitamura S.; Miyazaki Y.; Hiraoka S.; Nagasawa Y.; Toyota M.; Takakura R.; Kiyohara T.; Shinomura Y.; Matsuzawa Y.; PPARgamma agonists inhibit cell growth and suppress the expression of cyclin D1 and EGF-like growth factors in ras-transformed rat intestinal epithelial cells. Int J Cancer 2001,94(3),335-342","journal-title":"Int J Cancer"},{"key":"ref=52","first-page":"958","volume":"63","author":"Qin C.","year":"2003","unstructured":"Qin C.; Burghardt R.; Smith R.; Wormke M.; Stewart J.; Safe S.; Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells. Cancer Res 2003,63(5),958-964","journal-title":"Cancer Res"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"17088","DOI":"10.1074\/jbc.274.24.17088","volume":"274","author":"Morrison R.F.","year":"1999","unstructured":"Morrison R.F.; Farmer S.R.; Role of PPARgamma in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1\/Cip1), during adipogenesis. J Biol Chem 1999,274(24),17088-17097","journal-title":"J Biol Chem"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"8806","DOI":"10.1073\/pnas.95.15.8806","volume":"95","author":"Elstner E.","year":"1998","unstructured":"Elstner E.; M\u00fcller C.; Koshizuka K.; Williamson E.A.; Park D.; Asou H.; Shintaku P.; Said J.W.; Heber D.; Koeffler H.P.; Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998,95(15),8806-8811","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"582","DOI":"10.4161\/cc.4.4.1583","volume":"4","author":"Radhakrishnan S.K.","year":"2005","unstructured":"Radhakrishnan S.K.; Gartel A.L.; The PPAR-gamma agonist pioglitazone post-transcriptionally induces p21 in PC3 prostate cancer but not in other cell lines. Cell Cycle 2005,4(4),582-584","journal-title":"Cell Cycle"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/S0024-3205(01)01524-7","volume":"70","author":"Toyota M.","year":"2002","unstructured":"Toyota M.; Miyazaki Y.; Kitamura S.; Nagasawa Y.; Kiyohara T.; Shinomura Y.; Matsuzawa Y.; Peroxisome proliferator-activated receptor gamma reduces the growth rate of pancreatic cancer cells through the reduction of cyclin D1. Life Sci 2002,70(13),1565-1575","journal-title":"Life Sci"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1124\/jpet.103.053876","volume":"307","author":"Kim E.J.","year":"2003","unstructured":"Kim E.J.; Park K.S.; Chung S.Y.; Sheen Y.Y.; Moon D.C.; Song Y.S.; Kim K.S.; Song S.; Yun Y.P.; Lee M.K.; Oh K.W.; Yoon D.Y.; Hong J.T.; Peroxisome proliferator-activated receptor-gamma activator 15-deoxy-Delta12,14-prostaglandin J2 inhibits neuroblastoma cell growth through induction of apoptosis: Association with extracellular signal-regulated kinase signal pathway. J Pharmacol Exp Ther 2003,307(2),505-517","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1016\/S0024-3205(02)01510-2","volume":"70","author":"Chen G.G.","year":"2002","unstructured":"Chen G.G.; Lee J.F.; Wang S.H.; Chan U.P.; Ip P.C.; Lau W.Y.; Apoptosis induced by activation of peroxisome-proliferator activated receptor-gamma is associated with Bcl-2 and NF-kappaB in human colon cancer. Life Sci 2002,70(22),2631-2646","journal-title":"Life Sci"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.bbrc.2004.12.186","volume":"328","author":"Shen Z.N.","year":"2005","unstructured":"Shen Z.N.; Nishida K.; Doi H.; Oohashi T.; Hirohata S.; Ozaki T.; Yoshida A.; Ninomiya Y.; Inoue H.; Suppression of chondrosarcoma cells by 15-deoxy-Delta 12,14-prostaglandin J2 is associated with altered expression of Bax\/Bcl-xL and p21. Biochem Biophys Res Commun 2005,328(2),375-382","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.3748\/wjg.15.2234","volume":"15","author":"Tan X.W.","year":"2009","unstructured":"Tan X.W.; Xia H.; Xu J.H.; Cao J.G.; Induction of apoptosis in human liver carcinoma HepG2 cell line by 5-allyl-7-gen-difluoromethylenechrysin. World J Gastroenterol 2009,15(18),2234-2239","journal-title":"World J Gastroenterol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1046\/j.1471-4159.2002.00899.x","volume":"81","author":"Zander T.","year":"2002","unstructured":"Zander T.; Kraus J.A.; Grommes C.; Schlegel U.; Feinstein D.; Klockgether T.; Landreth G.; Koenigsknecht J.; Heneka M.T.; Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma. J Neurochem 2002,81(5),1052-1060","journal-title":"J Neurochem"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s11064-007-9475-x","volume":"33","author":"Kang D.W.","year":"2008","unstructured":"Kang D.W.; Choi C.H.; Park J.Y.; Kang S.K.; Kim Y.K.; Ciglitazone induces caspase-independent apoptosis through down-regulation of XIAP and survivin in human glioma cells. Neurochem Res 2008,33(3),551-561","journal-title":"Neurochem Res"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3892\/ijmm_00000273","volume":"24","author":"Liu J.J.","year":"2009","unstructured":"Liu J.J.; Guo Y.W.; Fang Z.G.; Si X.N.; Wu X.Y.; Liu P.Q.; Lin D.J.; Xiao R.Z.; Xu Y.; Wang C.Z.; Li X.D.; He Y.; Huang R.W.; Activation of peroxisome proliferator-activated receptor-gamma induces apoptosis on acute promyelocytic leukemia cells via downregulation of XIAP. Int J Mol Med 2009,24(5),623-632","journal-title":"Int J Mol Med"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nri2748","volume":"10","author":"Glass C.K.","year":"2010","unstructured":"Glass C.K.; Saijo K.; Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol 2010,10(5),365-376","journal-title":"Nat Rev Immunol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1038\/sj.onc.1209267","volume":"25","author":"Copland J.A.","year":"2006","unstructured":"Copland J.A.; Marlow L.A.; Kurakata S.; Fujiwara K.; Wong A.K.; Kreinest P.A.; Williams S.F.; Haugen B.R.; Klopper J.P.; Smallridge R.C.; Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1\/CIP1. Oncogene 2006,25(16),2304-2317","journal-title":"Oncogene"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/CAD.0b013e3280101006","volume":"18","author":"Fulzele S.V.","year":"2007","unstructured":"Fulzele S.V.; Chatterjee A.; Shaik M.S.; Jackson T.; Ichite N.; Singh M.; 15-Deoxy-Delta12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors. Anticancer Drugs 2007,18(1),65-78","journal-title":"Anticancer Drugs"},{"key":"ref=67","first-page":"6213","volume":"61","author":"Palakurthi S.S.","year":"2001","unstructured":"Palakurthi S.S.; Aktas H.; Grubissich L.M.; Mortensen R.M.; Halperin J.A.; Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res 2001,61(16),6213-6218","journal-title":"Cancer Res"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0014-2999(01)01577-1","volume":"436","author":"Abe A.","year":"2002","unstructured":"Abe A.; Kiriyama Y.; Hirano M.; Miura T.; Kamiya H.; Harashima H.; Tokumitsu Y.; Troglitazone suppresses cell growth of KU812 cells independently of PPARgamma. Eur J Pharmacol 2002,436(1-2),7-13","journal-title":"Eur J Pharmacol"},{"key":"ref=69","first-page":"13","author":"Smith U.","year":"2001","unstructured":"Smith U.; Pioglitazone: Mechanism of action. Int J Clin Pract Suppl 2001(121),13-18","journal-title":"Int J Clin Pract Suppl"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/cr.2009.53","volume":"19","author":"Li X.","year":"2009","unstructured":"Li X.; Yang X.; Xu Y.; Jiang X.; Li X.; Nan F.; Tang H.; Troglitazone inhibits cell proliferation by attenuation of epidermal growth factor receptor signaling independent of peroxisome proliferator-activated receptor gamma. Cell Res 2009,19(6),720-732","journal-title":"Cell Res"},{"key":"ref=71","first-page":"3479","volume":"32","author":"Rogenhofer S.","year":"2012","unstructured":"Rogenhofer S.; Ellinger J.; Kahl P.; Stoehr C.; Hartmann A.; Engehausen D.; Wieland W.F.; M\u00fcller S.C.; Hofst\u00e4dter F.; Walter B.; Enhanced expression of peroxisome proliferate-activated receptor gamma (PPAR-\u03b3) in advanced prostate cancer. Anticancer Res 2012,32(8),3479-3483","journal-title":"Anticancer Res"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1073\/pnas.94.1.237","volume":"94","author":"Tontonoz P.","year":"1997","unstructured":"Tontonoz P.; Singer S.; Forman B.M.; Sarraf P.; Fletcher J.A.; Fletcher C.D.; Brun R.P.; Mueller E.; Altiok S.; Oppenheim H.; Evans R.M.; Spiegelman B.M.; Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA 1997,94(1),237-241","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/sj.bjc.6601306","volume":"89","author":"Debrock G.","year":"2003","unstructured":"Debrock G.; Vanhentenrijk V.; Sciot R.; Debiec-Rychter M.; Oyen R.; Van Oosterom A.; A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer 2003,89(8),1409-1412","journal-title":"Br J Cancer"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1093\/carcin\/bgh160","volume":"25","author":"Nicol C.J.","year":"2004","unstructured":"Nicol C.J.; Yoon M.; Ward J.M.; Yamashita M.; Fukamachi K.; Peters J.M.; Gonzalez F.J.; PPARgamma influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis 2004,25(9),1747-1755","journal-title":"Carcinogenesis"},{"key":"ref=75","first-page":"357","volume":"1","author":"Kopelovich L.","year":"2002","unstructured":"Kopelovich L.; Fay J.R.; Glazer R.I.; Crowell J.A.; Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents. Mol Cancer Ther 2002,1(5),357-363","journal-title":"Mol Cancer Ther"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1016\/j.ijrobp.2012.11.040","volume":"85","author":"Han E.J.","year":"2013","unstructured":"Han E.J.; Im C.N.; Park S.H.; Moon E.Y.; Hong S.H.; Combined treatment with peroxisome proliferator-activated receptor (PPAR) gamma ligands and gamma radiation induces apoptosis by PPAR\u03b3-independent up-regulation of reactive oxygen species-induced deoxyribonucleic acid damage signals in non-small cell lung cancer cells. Int J Radiat Oncol Biol Phys 2013,85(5),e239-e248","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.redox.2012.12.006","volume":"1","author":"Khoo N.K.","year":"2013","unstructured":"Khoo N.K.; Hebbar S.; Zhao W.; Moore S.A.; Domann F.E.; Robbins M.E.; Differential activation of catalase expression and activity by PPAR agonists: implications for astrocyte protection in anti-glioma therapy. Redox Biol 2013,1,70-79","journal-title":"Redox Biol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.lungcan.2015.11.005","volume":"90","author":"Mangoni M.","year":"2015","unstructured":"Mangoni M.; Sottili M.; Gerini C.; Bonomo P.; Bottoncetti A.; Castiglione F.; Franzese C.; Cassani S.; Greto D.; Masoni T.; Meattini I.; Pallotta S.; Passeri A.; Pupi A.; Vanzi E.; Biti G.; Livi L.; A PPAR-gamma agonist attenuates pulmonary injury induced by irradiation in a murine model. Lung Cancer 2015,90(3),405-409","journal-title":"Lung Cancer"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1177\/2050640616640443","volume":"5","author":"Mangoni M.","year":"2017","unstructured":"Mangoni M.; Sottili M.; Gerini C.; Desideri I.; Bastida C.; Pallotta S.; Castiglione F.; Bonomo P.; Meattini I.; Greto D.; Cappelli S.; Di Brina L.; Loi M.; Biti G.; Livi L.; A PPAR-gamma agonist protects from radiation-induced intestinal toxicity. United European Gastroenterol J 2017,5(2),218-226","journal-title":"United European Gastroenterol J"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.oraloncology.2016.11.018","volume":"64","author":"Mangoni M.","year":"2017","unstructured":"Mangoni M.; Sottili M.; Gerini C.; Desideri I.; Bastida C.; Pallotta S.; Castiglione F.; Bonomo P.; Meattini I.; Greto D.; Olmetto E.; Terziani F.; Becherini C.; Delli Paoli C.; Trombetta L.; Loi M.; Biti G.; Livi L.; A PPAR gamma agonist protects against oral mucositis induced by irradiation in a murine model. Oral Oncol 2017,64,52-58","journal-title":"Oral Oncol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.2174\/1389450119666180131105158","volume":"19","author":"Kaur S.","year":"2018","unstructured":"Kaur S.; Nag A.; Singh A.K.; Sharma K.; PPAR\u03b3-targeting Potential for Radioprotection. Curr Drug Targets 2018,19(15),1818-1830","journal-title":"Curr Drug Targets"},{"key":"ref=82","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317716501","volume":"39","author":"Yousefi B.","year":"2017","unstructured":"Yousefi B.; Azimi A.; Majidinia M.; Shafiei-Irannejad V.; Badalzadeh R.; Baradaran B.; Zarghami N.; Samadi N.; Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPAR\u03b3-dependent manner in leukemia cells. Tumour Biol 2017,39(10)","journal-title":"Tumour Biol"},{"key":"ref=83","first-page":"177","volume":"11","author":"Abbasi M.M.","year":"2016","unstructured":"Abbasi M.M.; Valizadeh H.; Hamishehkar H.; Zakeri-Milani P.; Inhibition of P-glycoprotein expression and function by anti-diabetic drugs gliclazide, metformin, and pioglitazone in vitro and in situ. Res Pharm Sci 2016,11(3),177-186","journal-title":"Res Pharm Sci"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1593\/neo.08134","volume":"10","author":"Reddy R.C.","year":"2008","unstructured":"Reddy R.C.; Srirangam A.; Reddy K.; Chen J.; Gangireddy S.; Kalemkerian G.P.; Standiford T.J.; Keshamouni V.G.; Chemotherapeutic drugs induce PPAR-gamma expression and show sequence-specific synergy with PPAR-gamma ligands in inhibition of non-small cell lung cancer. Neoplasia 2008,10(6),597-603","journal-title":"Neoplasia"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1111\/j.1349-7006.2010.01632.x","volume":"101","author":"Hamaguchi N.","year":"2010","unstructured":"Hamaguchi N.; Hamada H.; Miyoshi S.; Irifune K.; Ito R.; Miyazaki T.; Higaki J.; In vitro and in vivo therapeutic efficacy of the PPAR-\u03b3 agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth. Cancer Sci 2010,101(9),1955-1964","journal-title":"Cancer Sci"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"6478","DOI":"10.1158\/1078-0432.CCR-08-1128","volume":"14","author":"Girnun G.D.","year":"2008","unstructured":"Girnun G.D.; Chen L.; Silvaggi J.; Drapkin R.; Chirieac L.R.; Padera R.F.; Upadhyay R.; Vafai S.B.; Weissleder R.; Mahmood U.; Naseri E.; Buckley S.; Li D.; Force J.; McNamara K.; Demetri G.; Spiegelman B.M.; Wong K.K.; Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin Cancer Res 2008,14(20),6478-6486","journal-title":"Clin Cancer Res"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ccr.2007.02.025","volume":"11","author":"Girnun G.D.","year":"2007","unstructured":"Girnun G.D.; Naseri E.; Vafai S.B.; Qu L.; Szwaya J.D.; Bronson R.; Alberta J.A.; Spiegelman B.M.; Synergy between PPARgamma ligands and platinum-based drugs in cancer. Cancer Cell 2007,11(5),395-406","journal-title":"Cancer Cell"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/1471-2407-9-107","volume":"9","author":"Tikoo K.","year":"2009","unstructured":"Tikoo K.; Kumar P.; Gupta J.; Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benzaanthracene (DMBA) induced breast cancer rats. BMC Cancer 2009,9,107","journal-title":"BMC Cancer"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1093\/ndt\/gfl194","volume":"21","author":"Lee S.","year":"2006","unstructured":"Lee S.; Kim W.; Moon S.O.; Sung M.J.; Kim D.H.; Kang K.P.; Jang Y.B.; Lee J.E.; Jang K.Y.; Park S.K.; Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrol Dial Transplant 2006,21(8),2096-2105","journal-title":"Nephrol Dial Transplant"},{"key":"ref=90","author":"Wu K.","year":"2019","unstructured":"Wu K.; Hu Y.; Yan K.; Qi Y.; Zhang C.; Zhu D.; Liu D.; Zhao S.; microRNA-10b confers cisplatin resistance by activating AKT\/mTOR\/P70S6K signaling via targeting PPARgamma in esophageal cancer. J Cell Physiol 2019","journal-title":"J Cell Physiol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"6165","DOI":"10.1074\/jbc.M505266200","volume":"281","author":"Akasaki Y.","year":"2006","unstructured":"Akasaki Y.; Liu G.; Matundan H.H.; Ng H.; Yuan X.; Zeng Z.; Black K.L.; Yu J.S.; A peroxisome proliferator-activated receptor-gamma agonist, troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells. J Biol Chem 2006,281(10),6165-6174","journal-title":"J Biol Chem"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1042\/BCJ20160583","volume":"475","author":"Delgado J.L.","year":"2018","unstructured":"Delgado J.L.; Hsieh C.M.; Chan N.L.; Hiasa H.; Topoisomerases as anticancer targets. Biochem J 2018,475(2),373-398","journal-title":"Biochem J"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S0301-472X(03)00003-1","volume":"31","author":"Kanbe E.","year":"2003","unstructured":"Kanbe E.; Abe A.; Towatari M.; Kawabe T.; Saito H.; Emi N.; DR1-like element in human topoisomerase IIalpha gene involved in enhancement of etoposide-induced apoptosis by PPARgamma ligand. Exp Hematol 2003,31(4),300-308","journal-title":"Exp Hematol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.leukres.2006.03.029","volume":"30","author":"Gu C.","year":"2006","unstructured":"Gu C.; Ye T.; Wells R.A.; Synergistic effects of troglitazone in combination with cytotoxic agents in acute myelogenous leukaemia cells. Leuk Res 2006,30(11),1447-1451","journal-title":"Leuk Res"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejphar.2014.07.041","volume":"741","author":"de Sousa Cavalcante L.","year":"2014","unstructured":"de Sousa Cavalcante L.; Monteiro G.; Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol 2014,741,8-16","journal-title":"Eur J Pharmacol"},{"key":"ref=96","first-page":"679","volume":"40","author":"Koga H.","year":"2012","unstructured":"Koga H.; Selvendiran K.; Sivakumar R.; Yoshida T.; Torimura T.; Ueno T.; Sata M.; PPAR\u03b3 potentiates anticancer effects of gemcitabine on human pancreatic cancer cells. Int J Oncol 2012,40(3),679-685","journal-title":"Int J Oncol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1245\/s10434-017-5871-x","volume":"24","author":"Asukai K.","year":"2017","unstructured":"Asukai K.; Kawamoto K.; Eguchi H.; Konno M.; Asai A.; Iwagami Y.; Yamada D.; Asaoka T.; Noda T.; Wada H.; Gotoh K.; Nishida N.; Satoh T.; Doki Y.; Mori M.; Ishii H.; Micro-RNA-130a-3p Regulates gemcitabine resistance via pparg in cholangiocarcinoma. Ann Surg Oncol 2017,24(8),2344-2352","journal-title":"Ann Surg Oncol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3892\/ijo.2014.2709","volume":"46","author":"Zhang Y.","year":"2015","unstructured":"Zhang Y.; Luo H.Y.; Liu G.L.; Wang D.S.; Wang Z.Q.; Zeng Z.L.; Xu R.H.; Prognostic significance and therapeutic implications of peroxisome proliferator-activated receptor \u03b3 overexpression in human pancreatic carcinoma. Int J Oncol 2015,46(1),175-184","journal-title":"Int J Oncol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/PPO.0b013e3181b36264","volume":"15","author":"Saif M.W.","year":"2009","unstructured":"Saif M.W.; Oettle H.; Vervenne W.L.; Thomas J.P.; Spitzer G.; Visseren-Grul C.; Enas N.; Richards D.A.; Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas. Cancer J 2009,15(4),339-343","journal-title":"Cancer J"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/aps.2009.119","volume":"30","author":"Cao L.Q.","year":"2009","unstructured":"Cao L.Q.; Wang X.L.; Wang Q.; Xue P.; Jiao X.Y.; Peng H.P.; Lu H.W.; Zheng Q.; Chen X.L.; Huang X.H.; Fu X.H.; Chen J.S.; Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway. Acta Pharmacol Sin 2009,30(9),1316-1322","journal-title":"Acta Pharmacol Sin"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.3748\/wjg.v13.i10.1534","volume":"13","author":"Zhang Y.Q.","year":"2007","unstructured":"Zhang Y.Q.; Tang X.Q.; Sun L.; Dong L.; Qin Y.; Liu H.Q.; Xia H.; Cao J.G.; Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor gamma. World J Gastroenterol 2007,13(10),1534-1540","journal-title":"World J Gastroenterol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/hed.25017","volume":"40","author":"Sottili M.","year":"2018","unstructured":"Sottili M.; Mangoni M.; Gerini C.; Salvatore G.; Castiglione F.; Desideri I.; Bonomo P.; Meattini I.; Greto D.; Loi M.; Francolini G.; Perna M.; Grassi R.; Biti G.; Livi L.; Peroxisome proliferator activated receptor-gamma stimulation for prevention of 5-fluorouracil-induced oral mucositis in mice. Head Neck 2018,40(3),577-583","journal-title":"Head Neck"},{"key":"ref=103","first-page":"1083","volume":"21","author":"Papi A.","year":"2009","unstructured":"Papi A.; Rocchi P.; Ferreri A.M.; Guerra F.; Orlandi M.; Enhanced effects of PPARgamma ligands and RXR selective retinoids in combination to inhibit migration and invasiveness in cancer cells. Oncol Rep 2009,21(4),1083-1089","journal-title":"Oncol Rep"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000055271","volume":"57","author":"Hirase N.","year":"1999","unstructured":"Hirase N.; Yanase T.; Mu Y.; Muta K.; Umemura T.; Takayanagi R.; Nawata H.; Thiazolidinedione induces apoptosis and monocytic differentiation in the promyelocytic leukemia cell line HL60. Oncology 1999,57(Suppl. 2),17-26","journal-title":"Oncology"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1158\/1535-7163.1249.3.10","volume":"3","author":"Konopleva M.","year":"2004","unstructured":"Konopleva M.; Elstner E.; McQueen T.J.; Tsao T.; Sudarikov A.; Hu W.; Schober W.D.; Wang R.Y.; Chism D.; Kornblau S.M.; Younes A.; Collins S.J.; Koeffler H.P.; Andreeff M.; Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther 2004,3(10),1249-1262","journal-title":"Mol Cancer Ther"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.clim.2004.06.011","volume":"113","author":"Ray D.M.","year":"2004","unstructured":"Ray D.M.; Bernstein S.H.; Phipps R.P.; Human multiple myeloma cells express peroxisome proliferator-activated receptor gamma and undergo apoptosis upon exposure to PPARgamma ligands. Clin Immunol 2004,113(2),203-213","journal-title":"Clin Immunol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1532\/IJH97.A30615","volume":"85","author":"Lee Y.R.","year":"2007","unstructured":"Lee Y.R.; Yu H.N.; Noh E.M.; Kim J.S.; Song E.K.; Han M.K.; Kim B.S.; Lee S.H.; Parkd J.; Peroxisome proliferator-activated receptor gamma and retinoic acid receptor synergistically up-regulate the tumor suppressor PTEN in human promyeloid leukemia cells. Int J Hematol 2007,85(3),231-237","journal-title":"Int J Hematol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"5126","DOI":"10.1182\/blood-2009-07-216457","volume":"114","author":"Tallman M.S.","year":"2009","unstructured":"Tallman M.S.; Altman J.K.; How I treat acute promyelocytic leukemia. Blood 2009,114(25),5126-5135","journal-title":"Blood"},{"key":"ref=109","first-page":"1604","volume":"60","author":"Rubin G.L.","year":"2000","unstructured":"Rubin G.L.; Zhao Y.; Kalus A.M.; Simpson E.R.; Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 2000,60(6),1604-1608","journal-title":"Cancer Res"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/carcin\/22.9.1379","volume":"22","author":"Yang W.L.","year":"2001","unstructured":"Yang W.L.; Frucht H.; Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis 2001,22(9),1379-1383","journal-title":"Carcinogenesis"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1007\/s13277-013-0791-2","volume":"34","author":"Liu Y.","year":"2013","unstructured":"Liu Y.; Zhu Z.A.; Zhang S.N.; Mou J.; Liu L.; Cui T.; Pei D.S.; Combinational effect of PPAR\u03b3 agonist and RXR agonist on the growth of SGC7901 gastric carcinoma cells in vitro. Tumour Biol 2013,34(4),2409-2418","journal-title":"Tumour Biol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1111\/j.1471-4159.2009.06111.x","volume":"109","author":"Papi A.","year":"2009","unstructured":"Papi A.; Tatenhorst L.; Terwel D.; Hermes M.; Kummer M.P.; Orlandi M.; Heneka M.T.; PPARgamma and RXRgamma ligands act synergistically as potent antineoplastic agents in vitro and in vivo glioma models. J Neurochem 2009,109(6),1779-1790","journal-title":"J Neurochem"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1084\/jem.193.7.827","volume":"193","author":"Desreumaux P.","year":"2001","unstructured":"Desreumaux P.; Dubuquoy L.; Nutten S.; Peuchmaur M.; Englaro W.; Schoonjans K.; Derijard B.; Desvergne B.; Wahli W.; Chambon P.; Leibowitz M.D.; Colombel J.F.; Auwerx J.; Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)\/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 2001,193(7),827-838","journal-title":"J Exp Med"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s12094-009-0347-5","volume":"11","author":"Kocdor H.","year":"2009","unstructured":"Kocdor H.; Kocdor M.A.; Canda T.; Gurel D.; Cehreli R.; Yilmaz O.; Alakavuklar M.; Guner G.; Chemopreventive efficacies of rosiglitazone, fenretinide and their combination against rat mammary carcinogenesis. Clin Transl Oncol 2009,11(4),243-249","journal-title":"Clin Transl Oncol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jaad.2006.10.033","volume":"56","author":"Sepmeyer J.A.","year":"2007","unstructured":"Sepmeyer J.A.; Greer J.P.; Koyama T.; Zic J.A.; Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 2007,56(4),584-587","journal-title":"J Am Acad Dermatol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.2353\/ajpath.2009.081078","volume":"175","author":"Bonofiglio D.","year":"2009","unstructured":"Bonofiglio D.; Cione E.; Qi H.; Pingitore A.; Perri M.; Catalano S.; Vizza D.; Panno M.L.; Genchi G.; Fuqua S.A.; And\u00f2 S.; Combined low doses of PPARgamma and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells. Am J Pathol 2009,175(3),1270-1280","journal-title":"Am J Pathol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/nrc1751","volume":"5","author":"Demierre M.F.","year":"2005","unstructured":"Demierre M.F.; Higgins P.D.; Gruber S.B.; Hawk E.; Lippman S.M.; Statins and cancer prevention. Nat Rev Cancer 2005,5(12),930-942","journal-title":"Nat Rev Cancer"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1023\/A:1006481423298","volume":"19","author":"Kim W.S.","year":"2001","unstructured":"Kim W.S.; Kim M.M.; Choi H.J.; Yoon S.S.; Lee M.H.; Park K.; Park C.H.; Kang W.K.; Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 2001,19(1),81-83","journal-title":"Invest New Drugs"},{"key":"ref=119","first-page":"1099","volume":"51","author":"Lersch C.","year":"2004","unstructured":"Lersch C.; Schmelz R.; Erdmann J.; Hollweck R.; Schulte-Frohlinde E.; Eckel F.; Nader M.; Schusdziarra V.; Treatment of HCC with pravastatin, octreotide, or gemcitabine--a critical evaluation. Hepatogastroenterology 2004,51(58),1099-1103","journal-title":"Hepatogastroenterology"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.ejca.2004.12.013","volume":"41","author":"Knox J.J.","year":"2005","unstructured":"Knox J.J.; Siu L.L.; Chen E.; Dimitroulakos J.; Kamel-Reid S.; Moore M.J.; Chin S.; Irish J.; LaFramboise S.; Oza A.M.; A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer 2005,41(4),523-530","journal-title":"Eur J Cancer"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3109\/10428190109097663","volume":"40","author":"Minden M.D.","year":"2001","unstructured":"Minden M.D.; Dimitroulakos J.; Nohynek D.; Penn L.Z.; Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia. Leuk Lymphoma 2001,40(5-6),659-662","journal-title":"Leuk Lymphoma"},{"key":"ref=122","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/med.20162","volume":"30","author":"Jakobisiak M.","year":"2010","unstructured":"Jakobisiak M.; Golab J.; Statins can modulate effectiveness of antitumor therapeutic modalities. Med Res Rev 2010,30(1),102-135","journal-title":"Med Res Rev"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/ijc.23718","volume":"123","author":"Xiao H.","year":"2008","unstructured":"Xiao H.; Yang C.S.; Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention. Int J Cancer 2008,123(5),983-990","journal-title":"Int J Cancer"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1002\/ijc.23315","volume":"122","author":"Xiao H.","year":"2008","unstructured":"Xiao H.; Zhang Q.; Lin Y.; Reddy B.S.; Yang C.S.; Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer 2008,122(9),2115-2124","journal-title":"Int J Cancer"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.3109\/10428194.2010.486877","volume":"51","author":"Shanafelt T.D.","year":"2010","unstructured":"Shanafelt T.D.; Rabe K.G.; Kay N.E.; Zent C.S.; Call T.G.; Slager S.L.; Bowen D.A.; Schwager S.M.; Nowakowski G.S.; Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia. Leuk Lymphoma 2010,51(7),1233-1240","journal-title":"Leuk Lymphoma"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/S0016-5085(99)70342-2","volume":"117","author":"Agarwal B.","year":"1999","unstructured":"Agarwal B.; Rao C.V.; Bhendwal S.; Ramey W.R.; Shirin H.; Reddy B.S.; Holt P.R.; Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 1999,117(4),838-847","journal-title":"Gastroenterology"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s00280-010-1535-2","volume":"67","author":"Tapia-P\u00e9rez J.H.","year":"2011","unstructured":"Tapia-P\u00e9rez J.H.; Kirches E.; Mawrin C.; Firsching R.; Schneider T.; Cytotoxic effect of different statins and thiazolidinediones on malignant glioma cells. Cancer Chemother Pharmacol 2011,67(5),1193-1201","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s11060-010-0351-1","volume":"102","author":"Gehring S.","year":"2011","unstructured":"Gehring S.; Tapia-P\u00e9rez J.H.; Kirches E.; Firsching R.; Keilhoff G.; Schneider T.; Mawrin C.; Cytotoxic effects of statins and thiazolidinediones on meningioma cells. J Neurooncol 2011,102(3),383-393","journal-title":"J Neurooncol"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/ijc.21361","volume":"118","author":"Yao C.J.","year":"2006","unstructured":"Yao C.J.; Lai G.M.; Chan C.F.; Cheng A.L.; Yang Y.Y.; Chuang S.E.; Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. Int J Cancer 2006,118(3),773-779","journal-title":"Int J Cancer"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/ni.3384","volume":"17","author":"Lasry A.","year":"2016","unstructured":"Lasry A.; Zinger A.; Ben-Neriah Y.; Inflammatory networks underlying colorectal cancer. Nat Immunol 2016,17(3),230-240","journal-title":"Nat Immunol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1053\/j.seminoncol.2015.09.010","volume":"43","author":"Umar A.","year":"2016","unstructured":"Umar A.; Steele V.E.; Menter D.G.; Hawk E.T.; Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention. Semin Oncol 2016,43(1),65-77","journal-title":"Semin Oncol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/ijc.10278","volume":"98","author":"Nikitakis N.G.","year":"2002","unstructured":"Nikitakis N.G.; Hebert C.; Lopes M.A.; Reynolds M.A.; Sauk J.J.; PPARgamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells. Int J Cancer 2002,98(6),817-823","journal-title":"Int J Cancer"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2407-5-46","volume":"5","author":"Kohno H.","year":"2005","unstructured":"Kohno H.; Suzuki R.; Sugie S.; Tanaka T.; Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer 2005,5,46","journal-title":"BMC Cancer"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.1158\/0008-5472.CAN-04-3441","volume":"65","author":"Avis I.","year":"2005","unstructured":"Avis I.; Mart\u00ednez A.; Tauler J.; Zudaire E.; Mayburd A.; Abu-Ghazaleh R.; Ondrey F.; Mulshine J.L.; Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition. Cancer Res 2005,65(10),4181-4190","journal-title":"Cancer Res"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1001\/archderm.140.12.1504","volume":"140","author":"Coras B.","year":"2004","unstructured":"Coras B.; Hafner C.; Reichle A.; Hohenleutner U.; Szeimies R.M.; Landthaler M.; Vogt T.; Antiangiogenic therapy with pioglitazone, rofecoxib, and trofosfamide in a patient with endemic kaposi sarcoma. Arch Dermatol 2004,140(12),1504-1507","journal-title":"Arch Dermatol"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1002\/cncr.20574","volume":"101","author":"Reichle A.","year":"2004","unstructured":"Reichle A.; Bross K.; Vogt T.; Bataille F.; Wild P.; Berand A.; Krause S.W.; Andreesen R.; Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer 2004,101(10),2247-2256","journal-title":"Cancer"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000120028","volume":"73","author":"Hau P.","year":"2007","unstructured":"Hau P.; Kunz-Schughart L.; Bogdahn U.; Baumgart U.; Hirschmann B.; Weimann E.; Muhleisen H.; Ruemmele P.; Steinbrecher A.; Reichle A.; Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study. Oncology 2007,73(1-2),21-25","journal-title":"Oncology"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.bioorg.2017.02.011","volume":"71","author":"Jameera Begam A.","year":"2017","unstructured":"Jameera Begam A.; Jubie S.; Nanjan M.J.; Estrogen receptor agonists\/antagonists in breast cancer therapy: A critical review. Bioorg Chem 2017,71,257-274","journal-title":"Bioorg Chem"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.2174\/187152012803529664","volume":"12","author":"Kotta-Loizou I.","year":"2012","unstructured":"Kotta-Loizou I.; Giaginis C.; Theocharis S.; The role of peroxisome proliferator-activated receptor-\u03b3 in breast cancer. Anticancer Agents Med Chem 2012,12(9),1025-1044","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1365-2559.2005.02056.x","volume":"46","author":"Papadaki I.","year":"2005","unstructured":"Papadaki I.; Mylona E.; Giannopoulou I.; Markaki S.; Keramopoulos A.; Nakopoulou L.; PPARgamma expression in breast cancer: clinical value and correlation with ERbeta. Histopathology 2005,46(1),37-42","journal-title":"Histopathology"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.bbrc.2008.09.111","volume":"377","author":"Yu H.N.","year":"2008","unstructured":"Yu H.N.; Noh E.M.; Lee Y.R.; Roh S.G.; Song E.K.; Han M.K.; Lee Y.C.; Shim I.K.; Lee S.J.; Jung S.H.; Kim J.S.; Youn H.J.; Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells. Biochem Biophys Res Commun 2008,377(1),242-247","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1158\/0008-5472.CAN-04-1677","volume":"65","author":"Shiau C.W.","year":"2005","unstructured":"Shiau C.W.; Yang C.C.; Kulp S.K.; Chen K.F.; Chen C.S.; Huang J.W.; Chen C.S.; Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL\/Bcl-2 functions independently of PPARgamma. Cancer Res 2005,65(4),1561-1569","journal-title":"Cancer Res"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/mc.22837","volume":"57","author":"Li X.","year":"2018","unstructured":"Li X.; He J.; Li B.; Gao M.; Zeng Y.; Lian J.; Shi C.; Huang Y.; He F.; The PPAR\u03b3 agonist rosiglitazone sensitizes the BH3 mimetic (-)-gossypol to induce apoptosis in cancer cells with high level of Bcl-2. Mol Carcinog 2018,57(9),1213-1222","journal-title":"Mol Carcinog"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","volume":"14","author":"Manasanch E.E.","year":"2017","unstructured":"Manasanch E.E.; Orlowski R.Z.; Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol 2017,14(7),417-433","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s00018-009-8542-7","volume":"66","author":"von Schwarzenberg K.","year":"2009","unstructured":"von Schwarzenberg K.; Held S.A.; Schaub A.; Brauer K.M.; Bringmann A.; Brossart P.; Proteasome inhibition overcomes the resistance of renal cell carcinoma cells against the PPARgamma ligand troglitazone. Cell Mol Life Sci 2009,66(7),1295-1308","journal-title":"Cell Mol Life Sci"},{"key":"ref=146","first-page":"207","volume":"27","author":"Freudlsperger C.","year":"2007","unstructured":"Freudlsperger C.; Thies A.; Pf\u00fcller U.; Schumacher U.; The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-gamma agonist rosiglitazone in human melanoma cells. Anticancer Res 2007,27(1A),207-213","journal-title":"Anticancer Res"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"7037","DOI":"10.1073\/pnas.121145898","volume":"98","author":"Raught B.","year":"2001","unstructured":"Raught B.; Gingras A.C.; Sonenberg N.; The target of rapamycin (TOR) proteins. Proc Natl Acad Sci USA 2001,98(13),7037-7044","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=148","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026831","volume":"6","author":"Li Y.","year":"2016","unstructured":"Li Y.; Seto E.; HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med 2016,6(10)","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejphar.2018.07.057","volume":"835","author":"Heers H.","year":"2018","unstructured":"Heers H.; Stanislaw J.; Harrelson J.; Lee M.W.; Valproic acid as an adjunctive therapeutic agent for the treatment of breast cancer. Eur J Pharmacol 2018,835,61-74","journal-title":"Eur J Pharmacol"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"7561","DOI":"10.1128\/MCB.00605-06","volume":"26","author":"Annicotte J.S.","year":"2006","unstructured":"Annicotte J.S.; Iankova I.; Miard S.; Fritz V.; Sarruf D.; Abella A.; Berthe M.L.; No\u00ebl D.; Pillon A.; Iborra F.; Dubus P.; Maudelonde T.; Culine S.; Fajas L.; Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol 2006,26(20),7561-7574","journal-title":"Mol Cell Biol"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/j.1365-2141.2009.07902.x","volume":"147","author":"Aouali N.","year":"2009","unstructured":"Aouali N.; Palissot V.; El-Khoury V.; Moussay E.; Janji B.; Pierson S.; Brons N.H.; Kellner L.; Bosseler M.; Van Moer K.; Berchem G.; Peroxisome proliferator-activated receptor gamma agonists potentiate the cytotoxic effect of valproic acid in multiple myeloma cells. Br J Haematol 2009,147(5),662-671","journal-title":"Br J Haematol"},{"key":"ref=152","first-page":"1206","volume":"8","author":"Chang T.H.","year":"2002","unstructured":"Chang T.H.; Szabo E.; Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung. Clin Cancer Res 2002,8(4),1206-1212","journal-title":"Clin Cancer Res"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.4161\/cc.5.19.3259","volume":"5","author":"Zang C.","year":"2006","unstructured":"Zang C.; Liu H.; Waechter M.; Eucker J.; Bertz J.; Possinger K.; Koeffler H.P.; Elstner E.; Dual PPARalpha\/gamma ligand TZD18 either alone or in combination with imatinib inhibits proliferation and induces apoptosis of human CML cell lines. Cell Cycle 2006,5(19),2237-2243","journal-title":"Cell Cycle"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1182\/blood-2005-05-2103","volume":"107","author":"Liu H.","year":"2006","unstructured":"Liu H.; Zang C.; Fenner M.H.; Liu D.; Possinger K.; Koeffler H.P.; Elstner E.; Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha\/gamma ligand TZD18. Blood 2006,107(9),3683-3692","journal-title":"Blood"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.leukres.2008.11.023","volume":"33","author":"Bertz J.","year":"2009","unstructured":"Bertz J.; Zang C.; Liu H.; W\u00e4chter M.; Possinger K.; Koeffler H.P.; Elstner E.; Compound 48, a novel dual PPAR alpha\/gamma ligand, inhibits the growth of human CML cell lines and enhances the anticancer-effects of imatinib. Leuk Res 2009,33(5),686-692","journal-title":"Leuk Res"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nature15248","volume":"525","author":"Prost S.","year":"2015","unstructured":"Prost S.; Relouzat F.; Spentchian M.; Ouzegdouh Y.; Saliba J.; Massonnet G.; Beressi J.P.; Verhoeyen E.; Raggueneau V.; Maneglier B.; Castaigne S.; Chomienne C.; Chr\u00e9tien S.; Rousselot P.; Leboulch P.; Erosion of the chronic myeloid leukaemia stem cell pool by PPAR\u03b3 agonists. Nature 2015,525(7569),380-383","journal-title":"Nature"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"6e377","DOI":"10.1038\/bcj.2015.109","author":"Glodkowska-Mrowka E.","year":"2016","unstructured":"Glodkowska-Mrowka E.; Manda-Handzlik A.; Stelmaszczyk-Emmel A.; Seferynska I.; Stoklosa T.; Przybylski J.; Mrowka P.; PPAR\u03b3 ligands increase antileukemic activity of second- and thirdgeneration tyrosine kinase inhibitors in chronic myeloid leukemia cells. Blood Cancer J 2016,6e377","journal-title":"Blood Cancer J"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/cncr.30490","volume":"123","author":"Rousselot P.","year":"2017","unstructured":"Rousselot P.; Prost S.; Guilhot J.; Roy L.; Etienne G.; Legros L.; Charbonnier A.; Coiteux V.; Cony-Makhoul P.; Huguet F.; Cayssials E.; Cayuela J.M.; Relouzat F.; Delord M.; Bruzzoni-Giovanelli H.; Morisset L.; Mahon F.X.; Guilhot F.; Leboulch P.; French C.M.L.G.; Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study. Cancer French CML Group2017,123(10),1791-1799","journal-title":"Cancer"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3324\/haematol.2016.153270","volume":"102","author":"Wang J.","year":"2017","unstructured":"Wang J.; Lu L.; Kok C.H.; Saunders V.A.; Goyne J.M.; Dang P.; Leclercq T.M.; Hughes T.P.; White D.L.; Increased peroxisome proliferator-activated receptor \u03b3 activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells. Haematologica 2017,102(5),843-853","journal-title":"Haematologica"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.lungcan.2005.10.010","volume":"51","author":"Lee S.Y.","year":"2006","unstructured":"Lee S.Y.; Hur G.Y.; Jung K.H.; Jung H.C.; Lee S.Y.; Kim J.H.; Shin C.; Shim J.J.; In, K.H.; Kang, K.H.; Yoo, S.H. PPAR-gamma agonist increase gefitinib\u2019s antitumor activity through PTEN expression. Lung Cancer 2006,51(3),297-301","journal-title":"Lung Cancer"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"20087","DOI":"10.1074\/jbc.M110.191718","volume":"286","author":"Park B.H.","year":"2011","unstructured":"Park B.H.; Lee S.B.; Stolz D.B.; Lee Y.J.; Lee B.C.; Synergistic interactions between heregulin and peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist in breast cancer cells. J Biol Chem 2011,286(22),20087-20099","journal-title":"J Biol Chem"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"8951","DOI":"10.1002\/jcp.27565","volume":"234","author":"Manabe A.","year":"2019","unstructured":"Manabe A.; Furukawa C.; Hasegawa H.; Matsunaga T.; Endo S.; Ikari A.; Upregulation of transient receptor potential melastatin 6 channel expression by rosiglitazone and all-trans-retinoic acid in erlotinib-treated renal tubular epithelial cells. J Cell Physiol 2019,234(6),8951-8962","journal-title":"J Cell Physiol"},{"key":"ref=163","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6404638","author":"Chandra M.","year":"2017","unstructured":"Chandra M.; Miriyala S.; Panchatcharam M.; PPAR\u03b3 and its role in cardiovascular diseases. PPAR Res 2017","journal-title":"PPAR Res"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1096\/fj.04-3309fje","volume":"19","author":"Lee K.S.","year":"2005","unstructured":"Lee K.S.; Park S.J.; Hwang P.H.; Yi H.K.; Song C.H.; Chai O.H.; Kim J.S.; Lee M.K.; Lee Y.C.; PPAR-gamma modulates allergic inflammation through up-regulation of PTEN. FASEB J 2005,19(8),1033-1035","journal-title":"FASEB J"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.freeradbiomed.2016.06.023","volume":"100","author":"Corona J.C.","year":"2016","unstructured":"Corona J.C.; Duchen M.R.; PPAR\u03b3 as a therapeutic target to rescue mitochondrial function in neurological disease. Free Radic Biol Med 2016,100,153-163","journal-title":"Free Radic Biol Med"},{"key":"ref=166","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/124624","author":"Dantas A.T.","year":"2015","unstructured":"Dantas A.T.; Pereira M.C.; de Melo Rego M.J.; da Rocha L.F.; Pitta, Ida.R.; Marques, C.D.; Duarte, A.L.; Pitta, M.G. The role of PPAR Gamma in systemic sclerosis. PPAR Res 2015","journal-title":"PPAR Res"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.4049\/jimmunol.164.3.1364","volume":"164","author":"Clark R.B.","year":"2000","unstructured":"Clark R.B.; Bishop-Bailey D.; Estrada-Hernandez T.; Hla T.; Puddington L.; Padula S.J.; The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 2000,164(3),1364-1371","journal-title":"J Immunol"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/34178","volume":"391","author":"Ricote M.","year":"1998","unstructured":"Ricote M.; Li A.C.; Willson T.M.; Kelly C.J.; Glass C.K.; The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998,391(6662),79-82","journal-title":"Nature"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1006\/clim.2001.5181","volume":"103","author":"Padilla J.","year":"2002","unstructured":"Padilla J.; Leung E.; Phipps R.P.; Human B lymphocytes and B lymphomas express PPAR-gamma and are killed by PPAR-gamma agonists. Clin Immunol 2002,103(1),22-33","journal-title":"Clin Immunol"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41467-017-00147-w","volume":"8","author":"Korpal M.","year":"2017","unstructured":"Korpal M.; Puyang X.; Jeremy Wu Z.; Seiler R.; Furman C.; Oo H.Z.; Seiler M.; Irwin S.; Subramanian V.; Julie Joshi J.; Wang C.K.; Rimkunas V.; Tortora D.; Yang H.; Kumar N.; Kuznetsov G.; Matijevic M.; Chow J.; Kumar P.; Zou J.; Feala J.; Corson L.; Henry R.; Selvaraj A.; Davis A.; Bloudoff K.; Douglas J.; Kiss B.; Roberts M.; Fazli L.; Black P.C.; Fekkes P.; Smith P.G.; Warmuth M.; Yu L.; Hao M.H.; Larsen N.; Daugaard M.; Zhu P.; Evasion of immunosurveillance by genomic alterations of PPAR\u03b3\/RXR\u03b1 in bladder cancer. Nat Commun 2017,8(1),103","journal-title":"Nat Commun"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1084\/jem.20162069","volume":"214","author":"Nobs S.P.","year":"2017","unstructured":"Nobs S.P.; Natali S.; Pohlmeier L.; Okreglicka K.; Schneider C.; Kurrer M.; Sallusto F.; Kopf M.; PPAR\u03b3 in dendritic cells and T cells drives pathogenic type-2 effector responses in lung inflammation. J Exp Med 2017,214(10),3015-3035","journal-title":"J Exp Med"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"21865","DOI":"10.1074\/jbc.M115.663526","volume":"290","author":"Santha S.","year":"2015","unstructured":"Santha S.; Viswakarma N.; Das S.; Rana A.; Rana B.; Tumor Necrosis Factor-related Apoptosis-inducing ligand (TRAIL)-troglitazone-induced apoptosis in prostate cancer cells involve amp-activated protein kinase. J Biol Chem 2015,290(36),21865-21875","journal-title":"J Biol Chem"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"66892","DOI":"10.18632\/oncotarget.11834","volume":"7","author":"Santha S.","year":"2016","unstructured":"Santha S.; Davaakhuu G.; Basu A.; Ke R.; Das S.; Rana A.; Rana B.; Modulation of glycogen synthase kinase-3\u03b2 following TRAIL combinatorial treatment in cancer cells. Oncotarget 2016,7(41),66892-66905","journal-title":"Oncotarget"},{"key":"ref=174","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028354","volume":"6","author":"Plissonnier M.L.","year":"2011","unstructured":"Plissonnier M.L.; Fauconnet S.; Bittard H.; Lascombe I.; The antidiabetic drug ciglitazone induces high grade bladder cancer cells apoptosis through the up-regulation of TRAIL. PLoS One 2011,6(12)","journal-title":"PLoS One"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"107744","DOI":"10.18632\/oncotarget.22632","volume":"8","author":"Plissonnier M.L.","year":"2017","unstructured":"Plissonnier M.L.; Fauconnet S.; Bittard H.; Mougin C.; Rommelaere J.; Lascombe I.; Cell death and restoration of TRAIL-sensitivity by ciglitazone in resistant cervical cancer cells. Oncotarget 2017,8(64),107744-107762","journal-title":"Oncotarget"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"26819","DOI":"10.18632\/oncotarget.15819","volume":"8","author":"Nazim U.M.","year":"2017","unstructured":"Nazim U.M.; Moon J.H.; Lee Y.J.; Seol J.W.; Park S.Y.; PPAR\u03b3 activation by troglitazone enhances human lung cancer cells to TRAIL-induced apoptosis via autophagy flux. Oncotarget 2017,8(16),26819-26831","journal-title":"Oncotarget"},{"key":"ref=177","first-page":"42","volume":"1845","author":"Dicitore A.","year":"2014","unstructured":"Dicitore A.; Caraglia M.; Gaudenzi G.; Manfredi G.; Amato B.; Mari D.; Persani L.; Arra C.; Vitale G.; Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-\u03b3 (PPAR-\u03b3): At the cross-road of pancreatic cancer cell proliferation. Biochim Biophys Acta 2014,1845(1),42-52","journal-title":"Biochim Biophys Acta"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.biotechadv.2011.08.001","volume":"30","author":"Vitale G.","year":"2012","unstructured":"Vitale G.; Zappavigna S.; Marra M.; Dicitore A.; Meschini S.; Condello M.; Arancia G.; Castiglioni S.; Maroni P.; Bendinelli P.; Piccoletti R.; van Koetsveld P.M.; Cavagnini F.; Budillon A.; Abbruzzese A.; Hofland L.J.; Caraglia M.; The PPAR-\u03b3 agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-\u03b2 treated pancreatic cancer cells. Biotechnol Adv 2012,30(1),169-184","journal-title":"Biotechnol Adv"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1158\/2326-6066.CIR-17-0612","volume":"6","author":"Goyal G.","year":"2018","unstructured":"Goyal G.; Wong K.; Nirschl C.J.; Souders N.; Neuberg D.; Anandasabapathy N.; Dranoff G.; PPAR\u03b3 contributes to immunity induced by cancer cell vaccines that secrete GM-CSF. Cancer Immunol Res 2018,6(6),723-732","journal-title":"Cancer Immunol Res"},{"key":"ref=180","first-page":"3198","volume":"9","author":"Yang Z.","year":"2003","unstructured":"Yang Z.; Bagheri-Yarmand R.; Balasenthil S.; Hortobagyi G.; Sahin A.A.; Barnes C.J.; Kumar R.; HER2 regulation of peroxisome proliferator-activated receptor gamma (PPARgamma) expression and sensitivity of breast cancer cells to PPARgamma ligand therapy. Clin Cancer Res 2003,9(8),3198-3203","journal-title":"Clin Cancer Res"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"872","DOI":"10.2174\/1871520614666140528155118","volume":"14","author":"Pal T.","year":"2014","unstructured":"Pal T.; Joshi H.; Ramaa C.S.; Design and development of oxazol-5-ones as potential partial PPAR-\u03b3 agonist against cancer cell lines. Anticancer Agents Med Chem 2014,14(6),872-883","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1517\/13543784.2014.884708","volume":"23","author":"Joshi H.","year":"2014","unstructured":"Joshi H.; Pal T.; Ramaa C.S.; A new dawn for the use of thiazolidinediones in cancer therapy. Expert Opin Investig Drugs 2014,23(4),501-510","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.bbrc.2011.06.026","volume":"410","author":"Yamamoto Y.","year":"2011","unstructured":"Yamamoto Y.; Fujita M.; Koma H.; Yamamori M.; Nakamura T.; Okamura N.; Yagami T.; 15-Deoxy-\u039412,14-prostaglandin J2 enhanced the anti-tumor activity of camptothecin against renal cell carcinoma independently of topoisomerase-II and PPAR\u03b3 pathways. Biochem Biophys Res Commun 2011,410(3),563-567","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/BLO.0b013e31802b683c","volume":"454","author":"Haydon R.C.","year":"2007","unstructured":"Haydon R.C.; Luu H.H.; He T.C.; Osteosarcoma and osteoblastic differentiation: A new perspective on oncogenesis. Clin Orthop Relat Res 2007,454(454),237-246","journal-title":"Clin Orthop Relat Res"},{"key":"ref=185","first-page":"249","volume":"32","author":"Mr\u00f3wka P.","year":"2008","unstructured":"Mr\u00f3wka P.; Glodkowska E.; Nowis D.; Legat M.; Issat T.; Makowski M.; Szokalska A.; Janowska S.; Stoklosa T.; Jak\u00f3bisiak M.; Golab J.; Ciglitazone, an agonist of peroxisome proliferator-activated receptor gamma, exerts potentiated cytostatic\/cytotoxic effects against tumor cells when combined with lovastatin. Int J Oncol 2008,32(1),249-255","journal-title":"Int J Oncol"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.canlet.2010.09.014","volume":"300","author":"Kim B.M.","year":"2011","unstructured":"Kim B.M.; Maeng K.; Lee K.H.; Hong S.H.; Combined treatment with the Cox-2 inhibitor niflumic acid and PPAR\u03b3 ligand ciglitazone induces ER stress\/caspase-8-mediated apoptosis in human lung cancer cells. Cancer Lett 2011,300(2),134-144","journal-title":"Cancer Lett"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00432-011-0993-1","volume":"137","author":"Yokoyama Y.","year":"2011","unstructured":"Yokoyama Y.; Xin B.; Shigeto T.; Mizunuma H.; Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers. J Cancer Res Clin Oncol 2011,137(8),1219-1228","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00432-010-0952-2","volume":"137","author":"Br\u00e4utigam K.","year":"2011","unstructured":"Br\u00e4utigam K.; Biernath-W\u00fcpping J.; Bauerschlag D.O.; von Kaisenberg C.S.; Jonat W.; Maass N.; Arnold N.; Meinhold-Heerlein I.; Combined treatment with TRAIL and PPAR\u03b3 ligands overcomes chemoresistance of ovarian cancer cell lines. J Cancer Res Clin Oncol 2011,137(5),875-886","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1600-0609.2009.01277.x","volume":"83","author":"Huang H.","year":"2009","unstructured":"Huang H.; Wu D.; Fu J.; Chen G.; Chang W.; Chow H.C.; Leung A.Y.; Liang R.; All-trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells. Eur J Haematol 2009,83(3),191-202","journal-title":"Eur J Haematol"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.canlet.2005.09.010","volume":"240","author":"Cesario R.M.","year":"2006","unstructured":"Cesario R.M.; Stone J.; Yen W.C.; Bissonnette R.P.; Lamph W.W.; Differentiation and growth inhibition mediated via the RXR: PPARgamma heterodimer in colon cancer. Cancer Lett 2006,240(2),225-233","journal-title":"Cancer Lett"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3892\/ijo.2010.877","volume":"38","author":"Mansour M.","year":"2011","unstructured":"Mansour M.; Schwartz D.; Judd R.; Akingbemi B.; Braden T.; Morrison E.; Dennis J.; Bartol F.; Hazi A.; Napier I.; Abdel-Mageed A.B.; Thiazolidinediones\/PPAR\u03b3 agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer. Int J Oncol 2011,38(2),537-546","journal-title":"Int J Oncol"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/mc.20751","volume":"50","author":"Fu H.","year":"2011","unstructured":"Fu H.; Zhang J.; Pan J.; Zhang Q.; Lu Y.; Wen W.; Lubet R.A.; Szabo E.; Chen R.; Wang Y.; Chen D.R.; You M.; Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A\/J mice. Mol Carcinog 2011,50(12),913-921","journal-title":"Mol Carcinog"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00280-010-1294-0","volume":"67","author":"Gottfried E.","year":"2011","unstructured":"Gottfried E.; Rogenhofer S.; Waibel H.; Kunz-Schughart L.A.; Reichle A.; Wehrstein M.; Peuker A.; Peter K.; Hartmannsgruber G.; Andreesen R.; Kreutz M.; Pioglitazone modulates tumor cell metabolism and proliferation in multicellular tumor spheroids. Cancer Chemother Pharmacol 2011,67(1),117-126","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3857\/roj.2012.30.2.78","volume":"30","author":"An Z.","year":"2012","unstructured":"An Z.; Liu X.; Song H.; Choi C.; Kim W.D.; Yu J.R.; Park W.Y.; Effect of troglitazone on radiation sensitivity in cervix cancer cells. Radiat Oncol J 2012,30(2),78-87","journal-title":"Radiat Oncol J"},{"key":"ref=195","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/mc.20593","volume":"49","author":"Yan K.H.","year":"2010","unstructured":"Yan K.H.; Yao C.J.; Chang H.Y.; Lai G.M.; Cheng A.L.; Chuang S.E.; The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells. Mol Carcinog 2010,49(3),235-246","journal-title":"Mol Carcinog"}],"container-title":["Current Cancer Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/177250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:39:13Z","timestamp":1665189553000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/177250\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,19]]},"references-count":195,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3,19]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568009619666191209102015","relation":{},"ISSN":["1568-0096"],"issn-type":[{"value":"1568-0096","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3,19]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-07-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}